Junyu Guo1, John O. Glass1, Qing Ji1, Catherine A. Billups2, Najat C. Daw3, Wilburn E. Reddick1
1Translational Imaging Research, Radiological Sciences, St Jude Children's Research Hospital, Memphis, TN, United States; 2Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, United States; 3Division of Pediatrics, MD Anderson Cancer Center, Houston, TX, United States
We investigated the role of DCE-MRI in evaluating tumor histological response to preoperative chemotherapy and predicting overall and event-free survival (EFS) of pediatric patients with newly diagnosed nonmetastatic osteosarcoma in an international, multi-institutional trial. We found that DCE-MRI parameters Ktrans and vp at week 9 of neoadjuvant therapy could serve as surrogate biomarker for histological response. And DCE-MRI parameter δve, the difference of ve between outer and inner 50% of tumor at week 0, may be a true early prognostic factor for EFS and overall survival, which eventually could contribute to the development of risk-adapted therapy.